Cargando…
Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
Autores principales: | Guido, Bruna Cândido, Brandão, Douglas Cardoso, Barbosa, Ana Luisa Augusto, Vianna, Monique Jacob Xavier, Faro, Lucas, Ramos, Luciana Machado, Nihi, Fabíola, de Castro, Márcio Botelho, Neto, Brenno A.D., Corrêa, José Raimundo, Báo, Sônia Nair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518687/ https://www.ncbi.nlm.nih.gov/pubmed/36187557 http://dx.doi.org/10.18632/oncotarget.28266 |
Ejemplares similares
-
Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
por: Guido, Bruna Cândido, et al.
Publicado: (2021) -
Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features
por: Guido, Bruna C, et al.
Publicado: (2015) -
Triple A patient cells suffering from mitotic defects fail to localize PGRMC1 to mitotic kinetochore fibers
por: Jühlen, Ramona, et al.
Publicado: (2018) -
The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
por: Moens, Stijn, et al.
Publicado: (2021) -
The Aurora-A inhibitor MLN8237 affects multiple mitotic processes and induces dose-dependent mitotic abnormalities and aneuploidy
por: Asteriti, Italia Anna, et al.
Publicado: (2014)